China Grants CR Double-Crane Pharma's API Approval for Epilepsy Drug Ingredients
China's medical products administrator approved China Resources Double-Crane Pharmaceutical's (SHA:600062) active pharmaceutical ingredient application for valproic acid and sodium valproate, according to a Thursday filing with the Shanghai Stock Exchange.
Valproic acid and sodium valproate are indicated for the treatment of epilepsy and mania, the filing said.
CR Double-Crane's shares fell nearly 1% in recent trading.
Price (RMB): ¥21.15, Change: ¥-0.15, Percent Change: -0.70%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.